Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on March 9, 2026. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding an update on the Company's clinical development program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on clinical trial updates rather than financial performance data.
Material Changes and Clinical Update
On March 9, 2026, the Company issued a press release (Exhibit 99.1) providing an update on its Phase 1b norovirus challenge study. The study evaluates the Company's candidate, CDI-988, for its efficacy as both a preventive measure and a treatment for norovirus infections.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial outlook, or specific risk factors beyond the standard disclaimer that the information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific data points regarding the Phase 1b norovirus challenge study results.
- Verify the status of the CDI-988 clinical trial and any implications for future regulatory filings.
- Check subsequent filings for any financial impact related to the clinical trial progress or potential delays.